Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ACML
MCID: LKM063
MIFTS: 73

Leukemia, Chronic Myeloid (ACML)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Leukemia, Chronic Myeloid

About this section

MalaCards integrated aliases for Leukemia, Chronic Myeloid:

Name: Leukemia, Chronic Myeloid 58 54 76 13 39
Chronic Myelogenous Leukemia 12 77 54 26 60 76 30 6 15 17
Chronic Myeloid Leukemia 39 12 54 26 60 38 44 15
Cml 58 12 54 26 60 76
Chronic Granulocytic Leukemia 12 54 26 60
Myeloid Leukemia, Chronic 12 74
Leukemia, Myeloid, Chronic, Atypical, Bcr-Abl Negative 74
Atypical Chronic Myeloid Leukemia Bcr-Abl1 Negative 76
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive 45
Leukemia, Chronic Myeloid, Atypical 76
Leukemia, Chronic Myeloid, Somatic 58
Cml - Chronic Myelogenous Leukemia 12
Leukemia, Chronic Myelogenous 58
Chronic Myelocytic Leukemia 26
Leukemia, Myeloid, Chronic 41
Myeloid Leukemia Chronic 56
Acml 76
Cgl 26

Characteristics:

Orphanet epidemiological data:

60
chronic myeloid leukemia
Inheritance: Not applicable; Prevalence: 1-9/100000 (Europe),1-9/100000 (France),1-9/100000 (United States); Age of onset: Adult;

OMIM:

58
Inheritance:
somatic mutation


HPO:

33
leukemia, chronic myeloid:
Inheritance somatic mutation


Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Cancer diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 35
Orphanet: 60  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:8552
OMIM 58 608232
KEGG 38 H00004
ICD9CM 36 205.1
MeSH 45 D015464
NCIt 51 C3174
SNOMED-CT 69 63364005 92818009
ICD10 via Orphanet 35 C92.1
UMLS via Orphanet 75 C0023473
Orphanet 60 ORPHA521
Sources

Summaries for Leukemia, Chronic Myeloid

About this section
NIH Rare Diseases : 54 The following summary is from Orphanet, a European reference portal for information on rare diseases and orphan drugs.Orpha Number: 521Disease definitionChronic myeloid leukaemia (CML) is the most common myeloproliferative disorder accounting for 15-20% of all leukaemia cases.EpidemiologyIts annual incidence has been estimated at between 1 and 1.5 cases per 100,000 and its prevalence at around 1 in 17,000.Clinical descriptionThe disease is typically triphasic with a chronic phase (CML-CP), accelerated phase (CML-AP) and blast phase (CML-BP). The majority of patients are diagnosed in the chronic phase and may be either asymptomatic (diagnosed through a routine white blood cell count) or present with fatigue, anaemia, weight loss, night sweats or splenomegaly.EtiologyCML is characterised by the presence of the Philadelphia chromosome, an abnormality resulting from a balanced translocation between chromosomes 9 and 22 (t(9;22)(q34;q11.2)). This translocation generates a BCR/ABL gene fusion encoding a constitutively active tyrosine kinase. CML does not appear to be an inherited disease and the factors leading to predisposition for the disorder remain largely unknown.Management and treatmentAlthough an allogeneic bone marrow transplant is viewed as the only curative treatment option, the prognosis for patients improved dramatically with the targeted development of imatinib mesylate. Imatinib mesylate is a competitive inhibitor of BCR/ABL tyrosine kinase activity and has held EU marketing authorisation as an Orphan drug for the treatment of CML since 2001.Visit the Orphanet disease page for more resources.

MalaCards based summary : Leukemia, Chronic Myeloid, also known as chronic myelogenous leukemia, is related to atypical chronic myeloid leukemia and philadelphia-negative chronic myeloid leukemia, and has symptoms including angina pectoris, edema and chest pain. An important gene associated with Leukemia, Chronic Myeloid is BCR (BCR Activator Of RhoGEF And GTPase), and among its related pathways/superpathways are Chronic myeloid leukemia and Endometrial cancer. The drugs Dasatinib and Lenograstim have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are myeloproliferative disorder and splenomegaly

Disease Ontology : 12 A myeloid leukemia that is characterized by over production of white blood cells.

Genetics Home Reference : 26 Chronic myeloid leukemia is a slow-growing cancer of the blood-forming tissue (bone marrow). Normal bone marrow produces red blood cells (erythrocytes) that carry oxygen, white blood cells (leukocytes) that protect the body from infection, and platelets (thrombocytes) that are involved in blood clotting. In chronic myeloid leukemia, the bone marrow produces too many white blood cells. Initially, these cells function relatively normally. However, as the condition progresses, immature white blood cells called myeloblasts (or blasts) accumulate in the blood and bone marrow. The overgrowth of myeloblasts impairs development of other blood cells, leading to a shortage of red blood cells (anemia) and platelets.

MedlinePlus : 44 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In chronic myeloid leukemia (CML), there are too many granulocytes, a type of white blood cell. Most people with CML have a gene mutation (change) called the Philadelphia chromosome. Sometimes CML does not cause any symptoms. If you have symptoms, they may include: Fatigue Weight loss Night sweats Fever Pain or a feeling of fullness below the ribs on the left side Tests that examine the blood and bone marrow diagnose CML. Treatments include chemotherapy, stem cell transplants, infusion of donated white blood cells following stem cell transplants, surgery to remove the spleen, and biologic and targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses substances that attack cancer cells without harming normal cells. NIH: National Cancer Institute

UniProtKB/Swiss-Prot : 76 Leukemia, chronic myeloid: A clonal myeloproliferative disorder of a pluripotent stem cell with a specific cytogenetic abnormality, the Philadelphia chromosome (Ph), involving myeloid, erythroid, megakaryocytic, B-lymphoid, and sometimes T-lymphoid cells, but not marrow fibroblasts. Leukemia, chronic myeloid, atypical: A myeloproliferative disorder that shares clinical and laboratory features with chronic myeloid leukemia but lacks the pathognomonic Philadelphia chromosome and the corresponding BCR/ABL1 fusion transcript. Features include myeloid predominance in the bone marrow, myeloid proliferation and low leukocyte alkaline phosphatase value, splenomegaly, hepatomegaly, elevated white blood cell count. Enlarged spleen may also be associated with a hypermetabolic state, fever, weight loss, and chronic fatigue. The enlarged liver may contribute to the patient's weight loss.

Wikipedia : 77 Chronic myeloid leukemia (CML), also known as chronic myelogenous leukemia, is a cancer of the white... more...

Description from OMIM: 608232
Sources

Related Diseases for Leukemia, Chronic Myeloid

About this section

Diseases in the Myeloid Leukemia family:

Leukemia, Acute Myeloid Leukemia, Chronic Myeloid
Subacute Myeloid Leukemia Acute Myeloid Leukemia with T(9;11)(p22;q23)
Acute Myeloid Leukemia with T(6;9)(p23;q34)

Diseases related to Leukemia, Chronic Myeloid via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 493)
# Related Disease Score Top Affiliating Genes
1 atypical chronic myeloid leukemia 35.2 ABL1 CSF3R JAK2 RUNX1 SETBP1
2 philadelphia-negative chronic myeloid leukemia 34.6 ABL1 BCR
3 leukemia 33.4 ABL1 BCR CSF3R HOTAIR JAK2 KIT
4 juvenile myelomonocytic leukemia 33.3 JAK2 NRAS RUNX1 SETBP1
5 myelodysplastic myeloproliferative cancer 33.0 ABL1 CSF3R JAK2 NRAS SETBP1
6 myeloid leukemia 32.0 ABL1 BCR CSF3R JAK2 KIT NRAS
7 myelofibrosis 31.5 JAK2 KIT MEG3 MIR223
8 essential thrombocythemia 31.4 ABL1 BCR JAK2 MIR223
9 chronic leukemia 31.4 BCR CSF3R JAK2 SETBP1
10 chronic myelomonocytic leukemia 31.4 CSF3R JAK2 KIT RUNX1 SETBP1
11 myeloma, multiple 31.3 H19 HOTAIR JAK2 KIT MEG3 NRAS
12 polycythemia vera 31.2 ABL1 H19 JAK2 KIT
13 leukemia, acute lymphoblastic 31.0 ABL1 BCR MIR203A MIR223 RUNX1
14 diffuse large b-cell lymphoma 30.9 HOTAIR HULC MIR10A
15 myeloproliferative neoplasm 30.9 ABL1 BCR H19 JAK2 KIT
16 kidney cancer 30.9 H19 HOTAIR MEG3 MIR20A
17 psoriasis 30.9 MIR10A MIR203A MIR20A
18 nasopharyngeal carcinoma 30.8 H19 HOTAIR HULC MEG3 NRAS
19 colorectal cancer 30.7 H19 HOTAIR HULC MEG3 MIR10A MIR203A
20 bone marrow cancer 30.7 ABL1 BCR CSF3R IRF8 JAK2 KIT
21 leukemia, acute myeloid 30.7 ABL1 BCR CSF3R HOTAIR JAK2 KIT
22 hepatocellular carcinoma 30.7 H19 HOTAIR HULC MEG3 MIR203A MIR20A
23 thyroid cancer, nonmedullary, 1 30.7 H19 HOTAIR HULC MEG3
24 melanoma 30.6 H19 HOTAIR MEG3 NRAS UCA1
25 myelodysplastic syndrome 30.6 ABL1 CSF3R JAK2 KIT MEG3 MIR10A
26 acute promyelocytic leukemia 30.6 CSF3R MIR223 NRAS RUNX1
27 thyroid cancer 30.6 H19 HOTAIR KIT NRAS UCA1
28 gastric adenocarcinoma 30.6 H19 HOTAIR KIT NRAS
29 bladder cancer 30.6 H19 HOTAIR HULC MEG3 MIR10A MIR203A
30 esophageal cancer 30.6 H19 HOTAIR HULC MEG3 MIR203A MIR223
31 prostate cancer 30.6 H19 HOTAIR HULC MEG3 MIR10A MIR203A
32 renal cell carcinoma, nonpapillary 30.5 H19 HOTAIR KIT UCA1
33 lung cancer 30.5 H19 HOTAIR KIT MEG3 MIR203A MIR20A
34 acute leukemia 30.1 JAK2 KIT RUNX1
35 pdgfrb-associated chronic eosinophilic leukemia 11.8
36 myelocytic leukemia-like syndrome, familial, chronic 11.2
37 lipodystrophy, congenital generalized, type 2 11.1
38 lipodystrophy, congenital generalized, type 1 11.1
39 chromosome 22q11.2 deletion syndrome, distal 10.7 BCR CRKL
40 neutrophilia, hereditary 10.7 CSF3R JAK2 MIR223
41 ovarian epithelial cancer 10.7 H19 HOTAIR HULC MEG3
42 core binding factor acute myeloid leukemia 10.7 JAK2 KIT NRAS RUNX1
43 functionless pituitary adenoma 10.7 HOTAIR MEG3
44 gastric cardia adenocarcinoma 10.7 H19 HOTAIR MEG3
45 pituitary adenoma 10.6 H19 HOTAIR MEG3 MIR223
46 pancreatic ductal adenocarcinoma 10.6 H19 HOTAIR MIR203A MIR223 UCA1
47 hematologic cancer 10.6 ABL1 BCR CSF3R JAK2 KIT RUNX1
48 8p11 myeloproliferative syndrome 10.6 BCR KIT RUNX1
49 oral squamous cell carcinoma 10.6 H19 HOTAIR MEG3 MIR10A MIR203A MIR223
50 osteogenic sarcoma 10.6 H19 HOTAIR HULC MEG3 UCA1

Comorbidity relations with Leukemia, Chronic Myeloid via Phenotypic Disease Network (PDN):


Acute Cystitis Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Leukemia, Chronic Myeloid:



Diseases related to Leukemia, Chronic Myeloid
Sources

Symptoms & Phenotypes for Leukemia, Chronic Myeloid

About this section

Human phenotypes related to Leukemia, Chronic Myeloid:

60 33 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 myeloproliferative disorder 60 33 obligate (100%) Obligate (100%) HP:0005547
2 splenomegaly 60 33 frequent (33%) Frequent (79-30%) HP:0001744
3 fever 60 33 frequent (33%) Frequent (79-30%) HP:0001945
4 fatigue 60 33 frequent (33%) Frequent (79-30%) HP:0012378
5 thrombocytopenia 60 33 frequent (33%) Frequent (79-30%) HP:0001873
6 thrombocytosis 60 33 frequent (33%) Frequent (79-30%) HP:0001894
7 leukocytosis 60 33 frequent (33%) Frequent (79-30%) HP:0001974
8 poor appetite 60 33 frequent (33%) Frequent (79-30%) HP:0004396
9 abnormal basophil morphology 33 frequent (33%) HP:0001912
10 abnormality of blood and blood-forming tissues 60 Frequent (79-30%)
11 abnormality of granulocytes 60 Frequent (79-30%)
12 abnormality of basophils 60 Frequent (79-30%)
13 chronic myelogenous leukemia 33 HP:0005506
14 ph-positive acute lymphoblastic leukemia 33 HP:0004848
15 reduced leukocyte alkaline phosphatase 33 HP:0004852

Symptoms via clinical synopsis from OMIM:

58
Hematology:
chronic myelogenous leukemia
ph-positive acute lymphoblastic leukemia

Laboratory Abnormalities:
low leukocyte alkaline phosphatase activity
presence of the philadelphia chromosome (translocation of 9q34 and 22q11) in greater than 95% of patients
two alternative chimeric oncogene products called p210(bcr-abl) and p185(bcr-abl)
detection by rt-pcr, southern blot analysis, and fish for primary diagnosis and follow up for residual disease

Clinical features from OMIM:

608232

UMLS symptoms related to Leukemia, Chronic Myeloid:


angina pectoris, edema, chest pain

GenomeRNAi Phenotypes related to Leukemia, Chronic Myeloid according to GeneCards Suite gene sharing:

27 (show all 39)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.02 ABL1 BCR
2 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.02 KIT
3 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.02 ABL1
4 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.02 BCR
5 Increased shRNA abundance (Z-score > 2) GR00366-A-116 10.02 CRKL
6 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.02 BCR SETBP1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.02 ABL1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.02 BCR
9 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.02 SETBP1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.02 CRKL
11 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.02 ABL1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-152 10.02 KIT
13 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.02 ABL1 KIT SETBP1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.02 CRKL
15 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.02 BCR SETBP1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-168 10.02 BCR
17 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.02 SETBP1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-170 10.02 KIT
19 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.02 CRKL
20 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.02 SETBP1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-190 10.02 SETBP1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.02 SETBP1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-2 10.02 BCR
24 Increased shRNA abundance (Z-score > 2) GR00366-A-208 10.02 CRKL
25 Increased shRNA abundance (Z-score > 2) GR00366-A-215 10.02 BCR
26 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.02 BCR
27 Increased shRNA abundance (Z-score > 2) GR00366-A-3 10.02 ABL1
28 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.02 ABL1 KIT
29 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.02 KIT
30 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.02 ABL1
31 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.02 ABL1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.02 CRKL
33 Increased shRNA abundance (Z-score > 2) GR00366-A-65 10.02 ABL1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-8 10.02 SETBP1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.02 SETBP1
36 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.02 ABL1 BCR
37 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.02 ABL1 BCR CRKL KIT SETBP1
38 Increased shRNA abundance (Z-score > 2) GR00366-A-9 10.02 KIT
39 Increased shRNA abundance (Z-score > 2) GR00366-A-99 10.02 KIT

MGI Mouse Phenotypes related to Leukemia, Chronic Myeloid:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 liver/biliary system MP:0005370 9.56 ABL1 BCR CRKL IRF8 JAK2 KIT
2 neoplasm MP:0002006 9.1 CRKL IRF8 JAK2 KIT NRAS RUNX1
Sources

Drugs & Therapeutics for Leukemia, Chronic Myeloid

About this section

Drugs for Leukemia, Chronic Myeloid (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 523)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dasatinib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 302962-49-8 3062316
2
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 135968-09-1
3
Cyclophosphamide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-18-0, 6055-19-2 2907
4
Thiotepa Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 52-24-4 5453
5
Benzocaine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 1994-09-7, 94-09-7 2337
6
tannic acid Approved Phase 4,Phase 2,Phase 3,Phase 1 1401-55-4
7
Tyrosine Approved, Investigational, Nutraceutical Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 60-18-4 6057
8
Lactitol Investigational Phase 4,Phase 2,Phase 3,Phase 1 585-88-6, 585-86-4 493591
9 Protein Kinase Inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
10 Imatinib Mesylate Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 220127-57-1 123596
11 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
12 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
13 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
14 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
15 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
16 interferons Phase 4,Phase 3,Phase 2,Phase 1
17 Interferon-alpha Phase 4,Phase 3,Phase 2,Phase 1
18 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
19 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
20 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
21 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
22 Antilymphocyte Serum Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
24 Tin Fluorides Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25
Hydroxyurea Approved Phase 3,Phase 2,Phase 1,Not Applicable 127-07-1 3657
26
Cytarabine Approved, Experimental, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 147-94-4, 65-46-3 6253
27
Idarubicin Approved Phase 3,Phase 2,Phase 1 58957-92-9 42890
28
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
29
Etoposide Approved Phase 3,Phase 2,Phase 1,Not Applicable 33419-42-0 36462
30
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable,Early Phase 1 75607-67-9, 21679-14-1 30751
31
Iron Approved, Experimental Phase 2, Phase 3,Phase 1,Not Applicable 7439-89-6, 15438-31-0 27284 23925
32
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
33
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
34
Cefepime Approved, Investigational Phase 3,Phase 1 88040-23-7 5479537
35
Ofloxacin Approved Phase 3 82419-36-1 4583
36
Mercaptopurine Approved Phase 3,Phase 1 50-44-2 667490
37
Melphalan Approved Phase 3,Phase 2,Phase 1,Not Applicable 148-82-3 460612 4053
38
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
39
leucovorin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 143 6006
40
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
41
Methotrexate Approved Phase 3,Phase 2,Phase 1,Not Applicable 1959-05-2, 59-05-2 126941
42
Sargramostim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 123774-72-1, 83869-56-1
43
Vincristine Approved, Investigational Phase 3,Phase 2,Phase 1 2068-78-2, 57-22-7 5978
44
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
45
Tacrolimus Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 6473866 445643 439492
46
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24280-93-1 446541
47
Vidarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24356-66-9 21704 32326
48
Methylprednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 83-43-2 6741
49
Prednisolone Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 50-24-8 5755
50
Prednisolone phosphate Approved, Vet_approved Phase 2, Phase 3,Phase 3,Phase 1,Not Applicable 302-25-0

Interventional clinical trials:

(show top 50) (show all 1213)
# Name Status NCT ID Phase Drugs
1 Efficacy and Safety of Imatinib Mesylate as First-line Treatment for the Patients With Chronic Phase of Chronic Myeloid Leukemia Unknown status NCT02317159 Phase 4 Imatinib
2 Multicenter, Phaseâ…£, Open Label Trial of Nilotinib in Adult Patients Diagnosed Philadelphia Chromosome Positive(Ph+) Chronic Myeloid Leukemia in CP/AP Intolerant to Dasatinib Unknown status NCT02389920 Phase 4 Nilotinib
3 Compliance: Role Emerges for Success in Chronic Myelogenous Leukaemia (CML): Evaluation aND Optimisation Unknown status NCT01243489 Phase 4
4 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
5 Study to Evaluate Nilotinib in Chronic Myelogenous Leukemia (CML) Patients With SubOptimal Response Completed NCT01043874 Phase 4 Nilotinib
6 Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia Completed NCT00390897 Phase 4 Glivec;Interferon
7 Study of Oral AMN107 (Nilotinib) in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Previously Enrolled to CAMN107A2109 Trial Completed NCT01368523 Phase 4 nilotinib
8 Study of Molecular Response in Adult Patients on Nilotinib With Philadelphia Chromosome Positive Chronic Myelogenous Leukemia (Ph+ CML) in Chronic Phase and a Suboptimal Molecular Response to Imatinib Completed NCT00644878 Phase 4 Nilotinib
9 Phase IV, Open-label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients With Chronic, Low-grade Non-Hematologic Toxicity to Imatinib Completed NCT01660906 Phase 4 Dasatinib
10 Study of Treatment With Nilotinib in Adult Patients With Imatinib - Resistant or - Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase Completed NCT00786812 Phase 4 Nilotinib
11 An Exploratory Trial to Assess the Improvement of Adverse Events in Chronic Myelogenous Leukemia Patients Treated With Imatinib When Switched to Nilotinib Treatment Completed NCT00980018 Phase 4 Nilotinib
12 Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML) Completed NCT00171899 Phase 4 imatinib mesylate
13 Gleevec Trial in Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Completed NCT00081926 Phase 4 Gleevec
14 CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Completed NCT01227577 Phase 4 Nilotinib
15 Efficacy and Safety of Nilotinib in CML-CP Completed NCT03332511 Phase 4 Nilotinib
16 Glivec in Pediatric Chronic Myeloid Leukemia (CML) Completed NCT00845221 Phase 4 Imatinib mesylate 100 mg (Glivec)
17 Nilotinib in Newly Diagnosed Adult Philadelphia Chromosome & /or BCR-ABL Positive Chronic Myeloid Leukaemia in Chronic Phase Completed NCT01061177 Phase 4 Nilotinib
18 Tasigna in Glivec-resistant or Intolerant Patients in CML Completed NCT01206088 Phase 4 nilotinib
19 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
20 Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia Recruiting NCT03216070 Phase 4 Dasatinib 50 MG
21 Sustained Treatment-free Remission in BCR-ABL+ Chronic Myeloid Leukemia Recruiting NCT02602314 Phase 4 Imatinib;Nilotinib
22 Study Assessing Deep Molecular Response in Adult Patients With CML in Chronic Phase Treated With Nilotinib Firstline. Recruiting NCT02546674 Phase 4 Nilotinib
23 Safety And Efficacy Study Of Bosutinib In Patients With Philadelphia Chromosome Positive Chronic Myeloid Leukemia Previously Treated With One Or More Tyrosine Kinase Inhibitors Active, not recruiting NCT02228382 Phase 4 Bosutinib
24 Validation of Digital-PCR Analysis Through Programmed Imatinib Interruption in PCR Negative CML Patients Active, not recruiting NCT01578213 Phase 4 Imatinib mesylate
25 Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib Terminated NCT00461929 Phase 4
26 A Study to Evaluate Efficacy and Safety of Glinib in Newly Diagnosed CML Patients Terminated NCT02204722 Phase 4 600mg/day of Imatinib;400mg/day of Imatinib
27 Study of Nilotinib in Ph+ CML-CP Patients With Low Imatinib Trough Plasma Concentrations Terminated NCT01131325 Phase 4 nilotinib
28 Efficacy and Safety Assessment of NIlotinib in CML Patients With Suboptimal Response on Imatinib Therapy Terminated NCT02086487 Phase 4 Nilotinib 300 mg.
29 Trial Evaluating Nilotinib as Treatment for Newly Diagnosed CML Patients in Accelerated Phase. Withdrawn NCT01605981 Phase 4 AMN107
30 Interferon Alfa in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia Unknown status NCT00002869 Phase 3 cytarabine;hydroxyurea
31 Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia Unknown status NCT00002771 Phase 3 busulfan;cytarabine;hydroxyurea;idarubicin
32 Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia Unknown status NCT00025402 Phase 3 busulfan;cyclophosphamide;cytarabine;etoposide;hydroxyurea;idarubicin
33 Comparing Imatinib Standard Dose With Imatinib High Dose Induction in Pretreated Chronic Myeloid Leukemia (CML) Patients in Chronic Phase Unknown status NCT00327262 Phase 3 Imatinib
34 Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion Unknown status NCT00966810 Phase 2, Phase 3
35 Efficacy of Nilotinib Versus Imatinib in Ph+ CML in Early CP Who Have a Suboptimal Molecular Response to Imatinib Unknown status NCT01400074 Phase 3 Nilotinib, Imatinib
36 Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy Unknown status NCT00297570 Phase 3 Pegylated Interferon and Imatinib
37 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
38 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
39 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
40 Thymoglobulin in Unrelated Hematopoietic Progenitor Cell Transplantation Unknown status NCT01217723 Phase 3
41 Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome Unknown status NCT00002989 Phase 3 busulfan;cyclophosphamide;idarubicin;melphalan
42 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
43 Safety and Efficacy of Nilotinib in Newly Diagnosed Chronic Myeloid Leukemia Patients Completed NCT01254188 Phase 3 Nilotinib
44 Efficacy and Safety of LBH589 in Adult Patients With Refractory Chronic Myeloid Leukemia (CML) in Chronic Phase Completed NCT00451035 Phase 2, Phase 3 LBH589
45 Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia Completed NCT00333840 Phase 3 imatinib mesilate;interferon-alpha (INF-a);cytarabine (ARA-C)
46 Comparative Bioequivalence Study in Adult Patients Suffering From Chronic Myeloid Leukemia & Gastrointestinal Stromal Tumor Under Fed Conditions Completed NCT02103322 Phase 2, Phase 3 Imatinib Mesylate Tablets, 400 mg;Imatinib Mesylate Tablets, 400 mg
47 Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase) Completed NCT00237120 Phase 3 Imatinib
48 Chronic Myelogenous Leukemia (CML) - Follow on: Study of BMS-354825 in Subjects With CML Completed NCT00123474 Phase 3 dasatinib;dasatinib;dasatinib;dasatinib
49 STI571 Compared With Interferon Alfa Plus Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia Completed NCT00006343 Phase 3 cytarabine;imatinib mesylate
50 A Phase III Study of Dasatinib vs Imatinib in Patients With Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Completed NCT00481247 Phase 3 Dasatinib;Imatinib

Search NIH Clinical Center for Leukemia, Chronic Myeloid

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Chronic Myeloid cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Leukemia, Chronic Myeloid:
Hemacord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Hematopoietic stem cells for treatment of hematologic malignancies
StemEx, umbilical cord blood stem/progenitor cells for hematological diseases
Embryonic/Adult Cultured Cells Related to Leukemia, Chronic Myeloid:
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD�) PMIDs: 9828244
Bone marrow-derived hematopoietic stem cells
Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724

Cochrane evidence based reviews: leukemia, myelogenous, chronic, bcr-abl positive

Sources

Genetic Tests for Leukemia, Chronic Myeloid

About this section

Genetic tests related to Leukemia, Chronic Myeloid:

# Genetic test Affiliating Genes
1 Chronic Myelogenous Leukemia 30 BCR
Sources

Anatomical Context for Leukemia, Chronic Myeloid

About this section

MalaCards organs/tissues related to Leukemia, Chronic Myeloid:

42
Myeloid, Bone, Bone Marrow, T Cells, Neutrophil, Testes, Spleen
Sources

Publications for Leukemia, Chronic Myeloid

About this section

Articles related to Leukemia, Chronic Myeloid:

(show top 50) (show all 3090)
# Title Authors Year
1
A Case of Chronic Myelogenous Leukemia Occurring in a Patient Treated for Essential Thrombocythemia. ( 30602717 )
2019
2
Erratum: BCR-ABL exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia. ( 31110760 )
2019
3
Does BCR-ABL transcript type influence the prognosis of patients in chronic myelogenous leukemia chronic phase? ( 31079657 )
2019
4
The Bone Phenotype and Pain Response to Pamidronate in Tyrosine Kinase Inhibitor-Treated Chronic Myelogenous Leukemia. ( 30997443 )
2019
5
Imatinib independent aberrant methylation of NOV/CCN3 in chronic myelogenous leukemia patients: a mechanism upstream of BCR-ABL1 function? ( 31014357 )
2019
6
Medicare and patient spending among beneficiaries diagnosed with chronic myelogenous leukemia. ( 30973642 )
2019
7
Sweet syndrome in a patient with chronic myelogenous leukemia under dasatinib treatment. ( 30932238 )
2019
8
Chronic myelogenous leukemia, a still unsolved problem: pitfalls and new therapeutic possibilities. ( 30880916 )
2019
9
Usnea Acid as Multidrug Resistance (MDR) Reversing Agent against Human Chronic Myelogenous Leukemia K562/ADR Cells via an ROS Dependent Apoptosis. ( 30886864 )
2019
10
Impact of Additional Chromosomal Aberrations on the Disease Progression of Chronic Myelogenous Leukemia. ( 30891424 )
2019
11
[Corrigendum] miR-9 regulates the multidrug resistance of chronic myelogenous leukemia by targeting ABCB1. ( 30896876 )
2019
12
Dasatinib-induced nephrotic syndrome in a patient with chronic myelogenous leukemia: a case report. ( 30845905 )
2019
13
Iridocorneal leukemic infiltrate in chronic myelogenous leukemia. ( 30851974 )
2019
14
Dasatinib for chronic myelogenous leukemia improves skin symptoms of systemic sclerosis. ( 30788724 )
2019
15
Concurrent JAK2-Positive Myeloproliferative Disorder and Chronic Myelogenous Leukemia: A Novel Entity? A Case Report With Review of the Literature. ( 30803277 )
2019
16
Renal dysfunction and anemia associated with long-term imatinib treatment in patients with chronic myelogenous leukemia. ( 30680668 )
2019
17
Bone mesenchymal stromal cells exhibit functional inhibition but no chromosomal aberrations in chronic myelogenous leukemia. ( 30655859 )
2019
18
In vitro activity of resorcinarene-chlorambucil conjugates for therapy in human chronic myelogenous leukemia cells. ( 30633576 )
2019
19
Assessment of soluble cytotoxic T lymphocyte-associated antigen-4, transforming growth factor β1, and platelet-derived microparticles during dasatinib therapy for patients with chronic myelogenous leukemia. ( 30588140 )
2019
20
Hydroxychavicol sensitizes imatinib-resistant chronic myelogenous leukemia cells to TRAIL-induced apoptosis by ROS-mediated IAP downregulation. ( 30418193 )
2019
21
A modified DAW-22 compound F-B1 inhibits Bcr/Abl and induces apoptosis in chronic myelogenous leukemia cells. ( 30422832 )
2019
22
Genomic amplification of BCR-ABL1 fusion gene and its impact on the disease progression mechanism in patients with chronic myelogenous leukemia. ( 30399426 )
2019
23
Practice Patterns of Physician Treatment for Pediatric Chronic Myelogenous Leukemia. ( 30267760 )
2019
24
Dasatinib-Induced Colitis in a Patient with Chronic Myelogenous Leukemia. ( 29998167 )
2018
25
A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells. ( 30687103 )
2018
26
A Rare Case of Chronic Myelogenous Leukemia Presenting as T-Cell Lymphoblastic Crisis. ( 30581639 )
2018
27
Induction of apoptosis and erythroid differentiation of human chronic myelogenous leukemia K562 cells by low concentrations of lidamycin. ( 30542729 )
2018
28
BCR-ABL exon 7 deletion and novel point mutation in patient with chronic myelogenous leukemia and TKI resistance. ( 30455891 )
2018
29
Preservation of Quiescent Chronic Myelogenous Leukemia Stem Cells by the Bone Marrow Microenvironment. ( 30411262 )
2018
30
LncRNA MALAT1 promotes cell proliferation and imatinib resistance by sponging miR-328 in chronic myelogenous leukemia. ( 30366670 )
2018
31
Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study. ( 30195076 )
2018
32
miR-217 sensitizes chronic myelogenous leukemia cells to tyrosine kinase inhibitors by targeting pro-oncogenic anterior gradient 2. ( 30195077 )
2018
33
A case report of bosutinib-induced interstitial granulomatous drug reaction in a patient with chronic myelogenous leukemia: a case report. ( 30214807 )
2018
34
Chronic myelogenous leukemia occurring in a chronic lymphocytic leukemia patient. ( 30147933 )
2018
35
Acute myeloid leukemia developed in Ph- cells with MLL gene amplification in a patient with chronic myelogenous leukemia. ( 29473433 )
2018
36
Chronic myelogenous leukemia presenting with osteonecrosis of the jaw as a rare but debilitating toxicity of dasatinib: a case report and literature review. ( 29941400 )
2018
37
Coronary Lesions in Takayasu Arteritis With Chronic Myelogenous Leukemia　- Intravascular Assessment With Optical Coherence Tomography and Fractional Flow Reserve. ( 29952342 )
2018
38
A Rare Case of Pediatric Chronic Myelogenous Leukemia Presenting With Severe Thrombocytosis Without Leukocytosis. ( 29187020 )
2018
39
Resveratrol inhibits STAT5 activation through the induction of SHP-1 and SHP-2 tyrosine phosphatases in chronic myelogenous leukemia cells. ( 29878900 )
2018
40
Integrated computational biology analysis to evaluate target genes for chronic myelogenous leukemia. ( 29901125 )
2018
41
Chronic myelogenous leukemia on target. ( 29905026 )
2018
42
A Systems Biology-Based Approach to Uncovering Molecular Mechanisms Underlying Effects of Traditional Chinese Medicine Qingdai in Chronic Myelogenous Leukemia, Involving Integration of Network Pharmacology and Molecular Docking Technology. ( 29934492 )
2018
43
Interferon-α Based Individualized Treatment of a High Risk Chronic Myelogenous Leukemia Patient Harboring T315I Mutation. ( 29945329 )
2018
44
Chronic Myelogenous Leukemia Presenting with Facial Nerve Palsy in an Infant. ( 30026776 )
2018
45
Inhibition of ER stress-related IRE1α/CREB/NLRP1 pathway promotes the apoptosis of human chronic myelogenous leukemia cell. ( 30055408 )
2018
46
Prognostic Implications of Derivative Chromosome 9 Deletions in Patients with Advanced-Stage Chronic Myelogenous Leukemia. ( 30055547 )
2018
47
Chronic myelogenous leukemia presenting with central nervous system infiltration, successfully treated with central nervous system-directed chemotherapy followed by allogeneic stem cell transplantation. ( 30078165 )
2018
48
Femtosecond laser pulse assisted photoporation for drug delivery in Chronic myelogenous leukemia cells. ( 30098520 )
2018
49
Dasatinib-induced anti-leukemia cellular immunity through a novel subset of CD57 positive helper/cytotoxic CD4 T cells in chronic myelogenous leukemia patients. ( 30151740 )
2018
50
Correction: CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia. ( 30181817 )
2018
Sources

Variations for Leukemia, Chronic Myeloid

About this section

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Chronic Myeloid:

76
# Symbol AA change Variation ID SNP ID
1 SETBP1 p.Asp868Asn VAR_063807 rs267607042
2 SETBP1 p.Gly870Ser VAR_063809 rs267607040
3 SETBP1 p.Ile871Thr VAR_063810 rs267607038
4 SETBP1 p.Glu858Lys VAR_069849 rs117870202

ClinVar genetic disease variations for Leukemia, Chronic Myeloid:

6 (show top 50) (show all 74)
# Gene Variation Type Significance SNP ID Assembly Location
1 SETBP1 NM_015559.3(SETBP1): c.2608G> A (p.Gly870Ser) single nucleotide variant Pathogenic rs267607040 GRCh37 Chromosome 18, 42531913: 42531913
2 SETBP1 NM_015559.3(SETBP1): c.2608G> A (p.Gly870Ser) single nucleotide variant Pathogenic rs267607040 GRCh38 Chromosome 18, 44951948: 44951948
3 ABL1 NM_007313.2(ABL1): c.1001C> T (p.Thr334Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913459 GRCh37 Chromosome 9, 133748283: 133748283
4 ABL1 NM_007313.2(ABL1): c.1001C> T (p.Thr334Ile) single nucleotide variant Pathogenic/Likely pathogenic rs121913459 GRCh38 Chromosome 9, 130872896: 130872896
5 ABL1 NM_007313.2(ABL1): c.763G> A (p.Glu255Lys) single nucleotide variant Pathogenic/Likely pathogenic rs387906517 GRCh37 Chromosome 9, 133738306: 133738306
6 ABL1 NM_007313.2(ABL1): c.763G> A (p.Glu255Lys) single nucleotide variant Pathogenic/Likely pathogenic rs387906517 GRCh38 Chromosome 9, 130862919: 130862919
7 ABL1 NM_007313.2(ABL1): c.814T> C (p.Tyr272His) single nucleotide variant Pathogenic/Likely pathogenic rs121913461 GRCh37 Chromosome 9, 133738357: 133738357
8 ABL1 NM_007313.2(ABL1): c.814T> C (p.Tyr272His) single nucleotide variant Pathogenic/Likely pathogenic rs121913461 GRCh38 Chromosome 9, 130862970: 130862970
9 ABL1 NM_007313.2(ABL1): c.1109T> C (p.Met370Thr) single nucleotide variant Pathogenic/Likely pathogenic rs121913457 GRCh37 Chromosome 9, 133748391: 133748391
10 ABL1 NM_007313.2(ABL1): c.1109T> C (p.Met370Thr) single nucleotide variant Pathogenic/Likely pathogenic rs121913457 GRCh38 Chromosome 9, 130873004: 130873004
11 JAK2 NM_004972.3(JAK2): c.1849G> T (p.Val617Phe) single nucleotide variant Pathogenic rs77375493 GRCh37 Chromosome 9, 5073770: 5073770
12 JAK2 NM_004972.3(JAK2): c.1849G> T (p.Val617Phe) single nucleotide variant Pathogenic rs77375493 GRCh38 Chromosome 9, 5073770: 5073770
13 NRAS NM_002524.3(NRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913250 GRCh37 Chromosome 1, 115258748: 115258748
14 NRAS NM_002524.3(NRAS): c.34G> C (p.Gly12Arg) single nucleotide variant Pathogenic rs121913250 GRCh38 Chromosome 1, 114716127: 114716127
15 KIT NM_000222.2(KIT): c.1621A> C (p.Met541Leu) single nucleotide variant Benign/Likely benign rs3822214 GRCh37 Chromosome 4, 55593464: 55593464
16 KIT NM_000222.2(KIT): c.1621A> C (p.Met541Leu) single nucleotide variant Benign/Likely benign rs3822214 GRCh38 Chromosome 4, 54727298: 54727298
17 BCR NM_004327.3(BCR): c.2699A> G (p.Asn900Ser) single nucleotide variant not provided rs752530462 GRCh37 Chromosome 22, 23631800: 23631800
18 BCR NM_004327.3(BCR): c.2699A> G (p.Asn900Ser) single nucleotide variant not provided rs752530462 GRCh38 Chromosome 22, 23289613: 23289613
19 BCR NM_004327.3(BCR): c.2707+21G> T single nucleotide variant not provided rs527236142 GRCh37 Chromosome 22, 23631829: 23631829
20 BCR NM_004327.3(BCR): c.2707+21G> T single nucleotide variant not provided rs527236142 GRCh38 Chromosome 22, 23289642: 23289642
21 BCR NM_004327.3(BCR): c.2750T> A (p.Val917Asp) single nucleotide variant not provided rs527236143 GRCh37 Chromosome 22, 23632568: 23632568
22 BCR NM_004327.3(BCR): c.2750T> A (p.Val917Asp) single nucleotide variant not provided rs527236143 GRCh38 Chromosome 22, 23290381: 23290381
23 BRAF NM_004333.4(BRAF): c.1742A> G (p.Asn581Ser) single nucleotide variant Likely pathogenic rs121913370 GRCh37 Chromosome 7, 140453193: 140453193
24 BRAF NM_004333.4(BRAF): c.1742A> G (p.Asn581Ser) single nucleotide variant Likely pathogenic rs121913370 GRCh38 Chromosome 7, 140753393: 140753393
25 CSF3R NM_156039.3(CSF3R): c.1853C> T (p.Thr618Ile) single nucleotide variant Pathogenic/Likely pathogenic rs796065343 GRCh37 Chromosome 1, 36933434: 36933434
26 CSF3R NM_156039.3(CSF3R): c.1853C> T (p.Thr618Ile) single nucleotide variant Pathogenic/Likely pathogenic rs796065343 GRCh38 Chromosome 1, 36467833: 36467833
27 ABL1 NM_005157.5(ABL1): c.730A> G (p.Met244Val) single nucleotide variant Likely pathogenic rs121913456 GRCh37 Chromosome 9, 133738330: 133738330
28 ABL1 NM_005157.5(ABL1): c.730A> G (p.Met244Val) single nucleotide variant Likely pathogenic rs121913456 GRCh38 Chromosome 9, 130862943: 130862943
29 ABL1 NM_005157.5(ABL1): c.742C> G (p.Leu248Val) single nucleotide variant Likely pathogenic rs121913455 GRCh37 Chromosome 9, 133738342: 133738342
30 ABL1 NM_005157.5(ABL1): c.742C> G (p.Leu248Val) single nucleotide variant Likely pathogenic rs121913455 GRCh38 Chromosome 9, 130862955: 130862955
31 ABL1 NM_005157.5(ABL1): c.749G> A (p.Gly250Glu) single nucleotide variant Likely pathogenic rs121913453 GRCh37 Chromosome 9, 133738349: 133738349
32 ABL1 NM_005157.5(ABL1): c.749G> A (p.Gly250Glu) single nucleotide variant Likely pathogenic rs121913453 GRCh38 Chromosome 9, 130862962: 130862962
33 ABL1 NM_005157.5(ABL1): c.756G> C (p.Gln252His) single nucleotide variant Likely pathogenic rs121913458 GRCh37 Chromosome 9, 133738356: 133738356
34 ABL1 NM_005157.5(ABL1): c.756G> C (p.Gln252His) single nucleotide variant Likely pathogenic rs121913458 GRCh38 Chromosome 9, 130862969: 130862969
35 ABL1 NM_007313.2(ABL1): c.813G> T (p.Gln271His) single nucleotide variant Likely pathogenic rs121913458 GRCh37 Chromosome 9, 133738356: 133738356
36 ABL1 NM_007313.2(ABL1): c.813G> T (p.Gln271His) single nucleotide variant Likely pathogenic rs121913458 GRCh38 Chromosome 9, 130862969: 130862969
37 ABL1 NM_005157.5(ABL1): c.758A> T (p.Tyr253Phe) single nucleotide variant Likely pathogenic rs121913460 GRCh37 Chromosome 9, 133738358: 133738358
38 ABL1 NM_005157.5(ABL1): c.758A> T (p.Tyr253Phe) single nucleotide variant Likely pathogenic rs121913460 GRCh38 Chromosome 9, 130862971: 130862971
39 ABL1 NM_007313.2(ABL1): c.820G> A (p.Glu274Lys) single nucleotide variant Likely pathogenic rs121913448 GRCh37 Chromosome 9, 133738363: 133738363
40 ABL1 NM_007313.2(ABL1): c.820G> A (p.Glu274Lys) single nucleotide variant Likely pathogenic rs121913448 GRCh38 Chromosome 9, 130862976: 130862976
41 ABL1 NM_005157.5(ABL1): c.764A> T (p.Glu255Val) single nucleotide variant Likely pathogenic rs121913449 GRCh37 Chromosome 9, 133738364: 133738364
42 ABL1 NM_005157.5(ABL1): c.764A> T (p.Glu255Val) single nucleotide variant Likely pathogenic rs121913449 GRCh38 Chromosome 9, 130862977: 130862977
43 ABL1 NM_005157.5(ABL1): c.847T> G (p.Phe283Val) single nucleotide variant Likely pathogenic rs1057519758 GRCh37 Chromosome 9, 133747540: 133747540
44 ABL1 NM_005157.5(ABL1): c.847T> G (p.Phe283Val) single nucleotide variant Likely pathogenic rs1057519758 GRCh38 Chromosome 9, 130872153: 130872153
45 ABL1 NM_005157.5(ABL1): c.951C> A (p.Phe317Leu) single nucleotide variant Likely pathogenic rs121913451 GRCh37 Chromosome 9, 133748290: 133748290
46 ABL1 NM_005157.5(ABL1): c.951C> A (p.Phe317Leu) single nucleotide variant Likely pathogenic rs121913451 GRCh38 Chromosome 9, 130872903: 130872903
47 ABL1 NM_007313.2(ABL1): c.1008C> G (p.Phe336Leu) single nucleotide variant Likely pathogenic rs121913451 GRCh37 Chromosome 9, 133748290: 133748290
48 ABL1 NM_007313.2(ABL1): c.1008C> G (p.Phe336Leu) single nucleotide variant Likely pathogenic rs121913451 GRCh38 Chromosome 9, 130872903: 130872903
49 ABL1 NM_005157.5(ABL1): c.1064A> G (p.Glu355Gly) single nucleotide variant Likely pathogenic rs121913450 GRCh37 Chromosome 9, 133748403: 133748403
50 ABL1 NM_005157.5(ABL1): c.1064A> G (p.Glu355Gly) single nucleotide variant Likely pathogenic rs121913450 GRCh38 Chromosome 9, 130873016: 130873016

Copy number variations for Leukemia, Chronic Myeloid from CNVD:

7 (show all 45)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 37133 1 858000 52858291 Copy numbercopy numb erLOH Chronic myeloid leukemia
2 44672 10 61218526 61336824 Translate D10S170 Chronic myelogenous leukemia
3 56890 11 61840484 62345935 Loss Chronic myeloid leukemia
4 59436 11 75208816 75845444 Loss Chronic myeloid leukemia
5 78023 13 48911492 50087172 Loss Chronic myeloid leukemia
6 83260 14 19767470 106339477 Gain Chronic myeloid leukemia
7 84230 14 24600000 33300000 Deletion Chronic myeloid leukemia
8 99762 16 28519207 31440323 Loss Chronic myeloid leukemia
9 138867 2 172217486 173146666 Loss Chronic myeloid leukemia
10 143230 2 234301355 238853232 Loss Chronic myeloid leukemia
11 162523 22 21962191 22180167 Loss Chronic myeloid leukemia
12 162524 22 21962191 22410163 Loss Chronic myeloid leukemia
13 162525 22 21962191 23748456 Loss Chronic myeloid leukemia
14 162526 22 21963005 23840758 Loss Chronic myeloid leukemia
15 162527 22 21965685 22103948 Loss Chronic myeloid leukemia
16 162528 22 21965685 22211587 Loss Chronic myeloid leukemia
17 162529 22 21965685 22575018 Loss Chronic myeloid leukemia
18 162530 22 21965685 23038955 Loss Chronic myeloid leukemia
19 162531 22 21965685 23404027 Loss Chronic myeloid leukemia
20 162532 22 21965685 23779268 Loss Chronic myeloid leukemia
21 162533 22 21969649 23264408 Loss Chronic myeloid leukemia
22 162539 22 21996232 23317147 Loss Chronic myeloid leukemia
23 162540 22 22020300 22659711 Loss Chronic myeloid leukemia
24 162567 22 22184646 22476629 Loss Chronic myeloid leukemia
25 162599 22 22374488 22513875 Loss Chronic myeloid leukemia
26 162992 22 23595985 23627388 Copy number Chronic myeloid leukemia
27 227187 7 65425674 65447246 Copy number GUSB Chronic myeloid leukemia
28 229935 7 97199324 142723486 Loss Chronic myeloid leukemia
29 231976 8 109706119 120929916 Loss Chronic myeloid leukemia
30 239048 8 3687491 5908007 Loss Chronic myeloid leukemia
31 247260 9 129645960 132672275 Loss Chronic myeloid leukemia
32 247319 9 130014643 132618574 Loss Chronic myeloid leukemia
33 247584 9 130432414 131425779 Loss Chronic myeloid leukemia
34 247725 9 130855419 132584828 Loss Chronic myeloid leukemia
35 247730 9 130896183 132618574 Loss Chronic myeloid leukemia
36 247834 9 131532978 132607062 Loss Chronic myeloid leukemia
37 247856 9 131641050 132590178 Loss Chronic myeloid leukemia
38 247886 9 131997035 132590178 Loss Chronic myeloid leukemia
39 247924 9 132362204 132593161 Loss Chronic myeloid leukemia
40 247932 9 132430323 132610819 Loss Chronic myeloid leukemia
41 248025 9 132985174 134219212 Loss Chronic myeloid leukemia
42 248051 9 133107127 133390056 Loss Chronic myeloid leukemia
43 248180 9 133589267 133763060 Copy number ABL1 Chronic myeloid leukemia
44 250432 9 212399 32604310 Loss Chronic myeloid leukemia
45 251914 9 3330 20811568 Copy numbercopy numb erLOH Chronic myeloid leukemia
Sources

Expression for Leukemia, Chronic Myeloid

About this section
Search GEO for disease gene expression data for Leukemia, Chronic Myeloid.
Sources

Pathways for Leukemia, Chronic Myeloid

About this section

Pathways related to Leukemia, Chronic Myeloid according to KEGG:

38
# Name Kegg Source Accession
1 Chronic myeloid leukemia hsa05220

Pathways related to Leukemia, Chronic Myeloid according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 38
Show member pathways
 12.59 ABL1 BCR CRKL KIT NRAS RUNX1
2
Pathways in cancer 38
12.28 ABL1 BCR CRKL CSF3R JAK2 KIT
3
NF-kappaB Signaling 4
12.27 IRF8 JAK2 KIT RUNX1
4
JAK-STAT signaling pathway (KEGG) 66
Show member pathways
 12.1 ABL1 CSF3R JAK2 NRAS
5
Tyrosine Kinases / Adaptors 4
11.72 ABL1 BCR CRKL JAK2 KIT
6
MicroRNAs in cancer 38
11.64 ABL1 CRKL MIR10A MIR203A MIR20A MIR223
7
Jak-Stat Signaling Pathway (sino) 68
11.57 ABL1 CSF3R JAK2 NRAS
8
Transcription_Transcription factor Tubby signaling pathways 23
11 ABL1 JAK2 NRAS
9
LncRNA-mediated mechanisms of therapeutic resistance 1
10.51 HOTAIR MEG3 UCA1
Sources

GO Terms for Leukemia, Chronic Myeloid

About this section

Cellular components related to Leukemia, Chronic Myeloid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 micro-ribonucleoprotein complex GO:0035068 9.1 H19 MEG3 MIR10A MIR203A MIR20A MIR223

Biological processes related to Leukemia, Chronic Myeloid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine-mediated signaling pathway GO:0019221 9.73 CRKL CSF3R JAK2 KIT
2 protein autophosphorylation GO:0046777 9.56 ABL1 BCR JAK2 KIT
3 peptidyl-tyrosine phosphorylation GO:0018108 9.5 ABL1 JAK2 KIT
4 cellular response to lipopolysaccharide GO:0071222 9.46 ABL1 BCR IRF8 MIR20A
5 gene silencing by miRNA GO:0035195 9.43 H19 MEG3 MIR10A MIR203A MIR20A MIR223
6 negative regulation of cell-cell adhesion GO:0022408 9.4 ABL1 JAK2
7 regulation of myeloid cell differentiation GO:0045637 9.37 CSF3R RUNX1
8 platelet-derived growth factor receptor signaling pathway GO:0048008 8.8 ABL1 BCR JAK2

Molecular functions related to Leukemia, Chronic Myeloid according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.26 MIR10A MIR203A MIR20A MIR223
2 protein tyrosine kinase activity GO:0004713 8.8 ABL1 JAK2 KIT
Sources

Sources for Leukemia, Chronic Myeloid

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....